Metastasis is the major cause of death for breast cancer patients. Tumors are heterogenous cellular entities composed of cancer cells and cells of the microenvironment in which they reside. A reciprocal dynamic interaction occurs between the tumor cells and their surrounding stroma under physiological and pathological conditions. This tumor-host communication interface mediates the escape of tumor cells at the primary site, survival of circulating cancer cells in the vasculature, and growth of metastatic cancer at secondary site. Each step of the metastatic process is accompanied by recruitment of stromal cells from the microenvironment and production of unique array of growth factors and chemokines. Stromal microenvironment may play active roles in breast cancer metastasis. Elucidating the types of cells recruited and signal pathways involved in the crosstalk between tumor cells and stromal cells will help identify novel strategies for cotargeting cancer cells and tumor stromal cells to suppress metastasis and improve patient outcome. 1. Introduction Breast cancer is the most common malignancy and the second major cause of mortality and morbidity in Western women [1]. The systemic outgrowth and spread of the cancer cells through a process known as metastasis is the main cause of deaths in these patients. Recently, disease-related mortality and metastasis have declined as a result of early diagnosis and application of adjuvant therapy. Mammographic screening, surgery, radiotherapy, chemotherapy, antibody therapy, and endocrine therapy facilitate the suppression of the metastatic dissemination of local tumor [2]. However, these treatments target the tumor cells and disregard the auxiliary cells present in the surrounding microenvironment that is also referred to as the stromal cells. These auxiliary cells, including myoepithelial cells, fibroblasts, myofibroblasts, endothelial cells, inflammatory cells, and bone-marrow-derived cells (BMDCs) such as macrophages, mast cells, neutrophils, and lymphocytes, are widely recognized to collaborate with cancerous cells and other host cells to create a tumor-permissive microenvironment capable of providing continuous support for tumor growth, progression, angiogenesis, invasion, and metastasis [3, 4]. Metastasis is the systemic dissemination of tumor cells at sites distinct from the primary lesion. It is a multistep process that involves detachment of cells from the primary tumor, followed by survival in the blood vessels or lymphatic system and finally development of secondary tumor. It is a poorly understood
References
[1]
B. Weigelt, J. L. Peterse, and L. J. Van't Veer, “Breast cancer metastasis: markers and models,” Nature Reviews Cancer, vol. 5, no. 8, pp. 591–602, 2005.
[2]
P. Eifel, J. A. Axelson, and J. Costa, “National institutes of health consensus development conference statement: adjuvant therapy for breast cancer, November 1–3, 2000,” Journal of the National Cancer Institute, vol. 93, no. 13, pp. 979–989, 2001.
[3]
J. A. Joyce and J. W. Pollard, “Microenvironmental regulation of metastasis,” Nature Reviews Cancer, vol. 9, no. 4, pp. 239–252, 2009.
[4]
Z. I. Khamis, Z. J. Sahab, S. W. Byers, and Q. X. Sang, “Novel stromal biomarkers in human breast cancer tissues provide evidence for the more malignant phenotype of estrogen receptor negative tumors,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 723650, 7 pages, 2011.
[5]
Z. I. Khamis, K. A. Iczkowski, and Q.-X. A. Sang, “Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: their prospects as therapeutic agents,” Medicinal Research Reviews. In press.
[6]
D. C. Allred, S. K. Mohsin, and S. A. W. Fuqua, “Histological and biological evolution of human premalignant breast disease,” Endocrine-Related Cancer, vol. 8, no. 1, pp. 47–61, 2001.
[7]
G. Arpino, R. Laucirica, and R. M. Elledge, “Premalignant and in situ breast disease: biology and clinical implications,” Annals of Internal Medicine, vol. 143, no. 6, pp. 446–457, 2005.
[8]
A. P. Brown, M. C. Ellison, P. J. Kenney et al., “Ductal carcinoma in situ of the breast,” New England Journal of Medicine, vol. 351, no. 4, pp. 399–402, 2004.
[9]
K. Polyak, “Breast cancer: origins and evolution,” Journal of Clinical Investigation, vol. 117, no. 11, pp. 3155–3163, 2007.
[10]
Y. G. Man, “Focal degeneration of aged or injured myoepithelial cells and the resultant auto-immunoreactions are trigger factors for breast tumor invasion,” Medical Hypotheses, vol. 69, no. 6, pp. 1340–1357, 2007.
[11]
Y. G. Man and Q. X. A. Sang, “The significance of focal myoepithelial cell layer disruptions in human breast tumor invasion: a paradigm shift from the "protease-centered" hypothesis,” Experimental Cell Research, vol. 301, no. 2, pp. 103–118, 2004.
[12]
Y. G. Man, T. Shen, J. Weisz et al., “A subset of in situ breast tumor cell clusters lacks expression of proliferation and progression related markers but shows signs of stromal and vascular invasion,” Cancer Detection and Prevention, vol. 29, no. 4, pp. 323–331, 2005.
[13]
S. H. Barsky, “Myoepithelial mRNA expression profiling reveals a common tumor-suppressor phenotype,” Experimental and Molecular Pathology, vol. 74, no. 2, pp. 113–122, 2003.
[14]
M. D. Sternlicht, S. Safarians, S. P. Rivera, and S. H. Barsky, “Characterizations of the extracellular matrix and proteinase inhibitor content of human myoepithelial tumors,” Laboratory Investigation, vol. 74, no. 4, pp. 781–796, 1996.
[15]
J. L. Jones, J. A. Shaw, J. H. Pringle, and R. A. Walker, “Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells,” Journal of Pathology, vol. 201, no. 4, pp. 562–572, 2003.
[16]
T. Gudjonsson, L. R？nnov-Jessen, R. Villadsen, F. Rank, M. J. Bissell, and O. W. Petersen, “Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition,” Journal of Cell Science, vol. 115, no. 1, pp. 39–50, 2002.
[17]
L. A. Gordon, R. A. Walker, and J. L. Jones, “Myoepithelial cells have an invasion-suppressor role in the human breast,” Journal of Pathology, vol. 192, p. 4A, 2000.
[18]
M. D. Sternlicht and S. H. Barsky, “The myoepithelial defense: a host defense against cancer,” Medical Hypotheses, vol. 48, no. 1, pp. 37–46, 1997.
[19]
M. D. Sternlicht, P. Kedeshian, Z. M. Shao, S. Safarians, and S. H. Barsky, “The human myoepithelial cell is a natural tumor suppressor,” Clinical Cancer Research, vol. 3, no. 11, pp. 1949–1958, 1997.
[20]
M. Nguyen, M. C. Lee, J. L. Wang et al., “The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype,” Oncogene, vol. 19, no. 31, pp. 3449–3459, 2000.
[21]
J. Teullière, M. M. Faraldo, M. A. Deugnier et al., “Targeted activation of β-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia,” Development, vol. 132, no. 2, pp. 267–277, 2005.
[22]
S. R. Lakhani and M. J. O'Hare, “The mammary myoepithelial cell—Cinderella or ugly sister?” Breast Cancer Research, vol. 3, no. 1, pp. 1–4, 2001.
[23]
M. Allinen, R. Beroukhim, L. Cai et al., “Molecular characterization of the tumor microenvironment in breast cancer,” Cancer Cell, vol. 6, no. 1, pp. 17–32, 2004.
[24]
M. Allinen, R. Beroukhim, L. Cai et al., “Molecular characterization of the tumor microenvironment in breast cancer,” Cancer Cell, vol. 6, no. 1, pp. 17–32, 2004.
[25]
A. Sadlonova, S. Mukherjee, D. B. Bowe et al., “Human breast fibroblasts inhibit growth of the MCF10AT xenograft model of proliferative breast disease,” American Journal of Pathology, vol. 170, no. 3, pp. 1064–1076, 2007.
[26]
J. T. Erler and V. M. Weaver, “Three-dimensional context regulation of metastasis,” Clinical and Experimental Metastasis, vol. 26, no. 1, pp. 35–49, 2009.
[27]
E. C. Finger and A. J. Giaccia, “Hypoxia, inflammation, and the tumor microenvironment in metastatic disease,” Cancer and Metastasis Reviews, vol. 29, no. 2, pp. 285–293, 2010.
[28]
R. Kalluri, “Basement membranes: structure, assembly and role in tumour angiogenesis,” Nature Reviews Cancer, vol. 3, no. 6, pp. 422–433, 2003.
[29]
M. Bauer, G. Su, C. Casper, R. He, W. Rehrauer, and A. Friedl, “Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast,” Oncogene, vol. 29, no. 12, pp. 1732–1740, 2010.
[30]
D. Liao, Y. Luo, D. Markowitz, R. Xiang, and R. A. Reisfeld, “Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model,” PLoS One, vol. 4, no. 11, Article ID e7965, 2009.
[31]
A. Sadlonova, D. B. Bowe, Z. Novak et al., “Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts,” Cancer Microenvironment, vol. 2, no. 1, pp. 9–21, 2009.
[32]
S.-W. Tyan, W.-H. Kuo, C.-K. Huang et al., “Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis,” PLoS One, vol. 6, no. 1, Article ID e15313, 2011.
[33]
A. K. Witkiewicz, J. Kline, M. Queenan et al., “Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers,” Cell Cycle, vol. 10, no. 11, pp. 1794–1809, 2011.
[34]
G. Bonuccelli, D. Whitaker-Menezes, R. Castello-Cros et al., “The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts,” Cell Cycle, vol. 9, no. 10, pp. 1960–1971, 2010.
[35]
P. Surowiak, D. Murawa, V. Materna et al., “Occurence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor,” Anticancer Research, vol. 27, no. 4C, pp. 2917–2924, 2007.
[36]
X. Guo, H. Oshima, T. Kitmura, M. M. Taketo, and M. Oshima, “Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer,” Journal of Biological Chemistry, vol. 283, no. 28, pp. 19864–19871, 2008.
[37]
L. M. Sobral, A. Bufalino, M. A. Lopes, E. Graner, T. Salo, and R. D. Coletta, “Myofibroblasts in the stroma of oral cancer promote tumorigenesis via secretion of activin A,” Oral Oncology, vol. 47, no. 9, pp. 840–846, 2011.
[38]
H. Denys, L. Derycke, A. Hendrix et al., “Differential impact of TGF-β and EGF on fibroblast differentiation and invasion reciprocally promotes colon cancer cell invasion,” Cancer Letters, vol. 266, no. 2, pp. 263–274, 2008.
[39]
Q. Yao, S. Cao, C. Li, A. Mengesha, B. Kong, and M. Wei, “Micro-RNA-21 regulates TGF-β-induced myofibroblast differentiation by targeting PDCD4 in tumor-stroma interaction,” International Journal of Cancer, vol. 128, no. 8, pp. 1783–1792, 2011.
[40]
K. Noma, K. S. M. Smalley, M. Lioni et al., “The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis,” Gastroenterology, vol. 134, no. 7, pp. 1981–1993, 2008.
[41]
B. Dirat, L. Bochet, M. Dabek et al., “Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion,” Cancer Research, vol. 71, no. 7, pp. 2455–2465, 2011.
[42]
M. Walter, S. Liang, S. Ghosh, P. J. Hornsby, and R. Li, “Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells,” Oncogene, vol. 28, no. 30, pp. 2745–2755, 2009.
[43]
P. S. Steeg, “Tumor metastasis: mechanistic insights and clinical challenges,” Nature Medicine, vol. 12, no. 8, pp. 895–904, 2006.
[44]
E. C. Kauffman, V. L. Robinson, W. M. Stadler, M. H. Sokoloff, and C. W. Rinker-Schaeffer, “Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site,” Journal of Urology, vol. 169, no. 3, pp. 1122–1133, 2003.
[45]
G. P. Gupta and J. Massagué, “Cancer metastasis: building a framework,” Cell, vol. 127, no. 4, pp. 679–695, 2006.
[46]
S. Koop, E. E. Schmidt, I. C. Macdonald et al., “Independence of metastatic ability and extravasation: metastatic ras-transformed and control fibroblasts extravasate equally well,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 20, pp. 11080–11084, 1996.
[47]
A. Zijlstra, R. Mellor, G. Panzarella et al., “A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction,” Cancer Research, vol. 62, no. 23, pp. 7083–7092, 2002.
[48]
R. Kalluri and M. Zeisberg, “Fibroblasts in cancer,” Nature Reviews Cancer, vol. 6, no. 5, pp. 392–401, 2006.
[49]
N. A. Bhowmick, E. G. Neilson, and H. L. Moses, “Stromal fibroblasts in cancer initiation and progression,” Nature, vol. 432, no. 7015, pp. 332–337, 2004.
[50]
F. Angeli, G. Koumakis, M. C. Chen, S. Kumar, and J. G. Delinassios, “Role of stromal fibroblasts in cancer: promoting or impeding?” Tumor Biology, vol. 30, no. 3, pp. 109–120, 2009.
[51]
C. Kuperwasser, T. Chavarria, M. Wu et al., “Reconstruction of functionally normal and malignant human breast tissues in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 14, pp. 4966–4971, 2004.
[52]
A. Orimo, P. B. Gupta, D. C. Sgroi et al., “Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion,” Cell, vol. 121, no. 3, pp. 335–348, 2005.
[53]
S. Ostrand-Rosenberg and P. Sinha, “Myeloid-derived suppressor cells: linking inflammation and cancer,” Journal of Immunology, vol. 182, no. 8, pp. 4499–4506, 2009.
[54]
F. Colotta, P. Allavena, A. Sica, C. Garlanda, and A. Mantovani, “Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability,” Carcinogenesis, vol. 30, no. 7, pp. 1073–1081, 2009.
[55]
L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002.
[56]
H. F. Dvorak, “Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing,” New England Journal of Medicine, vol. 315, no. 26, pp. 1650–1659, 1986.
[57]
X. J. Ma, S. Dahiya, E. Richardson, M. Erlander, and D. C. Sgroi, “Gene expression profiling of the tumor microenvironment during breast cancer progression,” Breast Cancer Research, vol. 11, no. 1, article no. R7, 2009.
[58]
P. Schedin and V. Borges, “Breaking down barriers: the importance of the stromal microenvironment in acquiring invasiveness in young women's breast cancer,” Breast Cancer Research, vol. 11, no. 2, article 102, 2009.
[59]
L. F. Brown, A. J. Guidi, S. J. Schnitt et al., “Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast,” Clinical Cancer Research, vol. 5, no. 5, pp. 1041–1056, 1999.
[60]
J. Yang, S. A. Mani, J. L. Donaher et al., “Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis,” Cell, vol. 117, no. 7, pp. 927–939, 2004.
[61]
J. Condeelis and J. E. Segall, “Intravital imaging of cell movement in tumours,” Nature Reviews Cancer, vol. 3, no. 12, pp. 921–930, 2003.
[62]
J. B. Wyckoff, Y. Wang, E. Y. Lin et al., “Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors,” Cancer Research, vol. 67, no. 6, pp. 2649–2656, 2007.
[63]
J. Wyckoff, W. Wang, E. Y. Lin et al., “A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors,” Cancer Research, vol. 64, no. 19, pp. 7022–7029, 2004.
[64]
S. Goswami, E. Sahai, J. B. Wyckoff et al., “Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop,” Cancer Research, vol. 65, no. 12, pp. 5278–5283, 2005.
[65]
J. S. Palumbo, “Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination,” Seminars in Thrombosis and Hemostasis, vol. 34, no. 2, pp. 154–160, 2008.
[66]
J. H. Im, W. Fu, H. Wang et al., “Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation,” Cancer Research, vol. 64, no. 23, pp. 8613–8619, 2004.
[67]
J. S. Palumbo, K. E. Talmage, J. V. Massari et al., “Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and -independent mechanisms,” Blood, vol. 110, no. 1, pp. 133–141, 2007.
[68]
J. M. Pawelek and A. K. Chakraborty, “Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis,” Nature Reviews Cancer, vol. 8, no. 5, pp. 377–386, 2008.
[69]
M. L. Criscuoli, M. Nguyen, and B. P. Eliceiri, “Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability,” Blood, vol. 105, no. 4, pp. 1508–1514, 2005.
[70]
B. Qian, Y. Deng, J. H. Im et al., “A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth,” PLoS One, vol. 4, no. 8, Article ID e6562, 2009.
[71]
B. Z. Qian and J. W. Pollard, “Macrophage diversity enhances tumor progression and metastasis,” Cell, vol. 141, no. 1, pp. 39–51, 2010.
[72]
I. J. Fidler, “The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited,” Nature Reviews Cancer, vol. 3, no. 6, pp. 453–458, 2003.
[73]
R. N. Kaplan, S. Rafii, and D. Lyden, “Preparing the "soil": the premetastatic niche,” Cancer Research, vol. 66, no. 23, pp. 11089–11093, 2006.
[74]
X. Lu, Q. Wang, G. Hu et al., “ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis,” Genes and Development, vol. 23, no. 16, pp. 1882–1894, 2009.
[75]
P. D. Bos, X. H. F. Zhang, C. Nadal et al., “Genes that mediate breast cancer metastasis to the brain,” Nature, vol. 459, no. 7249, pp. 1005–1009, 2009.
[76]
A. J. Minn, G. P. Gupta, P. M. Siegel et al., “Genes that mediate breast cancer metastasis to lung,” Nature, vol. 436, no. 7050, pp. 518–524, 2005.
[77]
G. P. Gupta, D. X. Nguyen, A. C. Chiang et al., “Mediators of vascular remodelling co-opted for sequential steps in lung metastasis,” Nature, vol. 446, no. 7137, pp. 765–770, 2007.
[78]
T. Oskarsson, S. Acharyya, X. H.-F. Zhang et al., “Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs,” Nature Medicine, vol. 17, no. 7, pp. 867–874, 2011.
[79]
R. N. Kaplan, R. D. Riba, S. Zacharoulis et al., “VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche,” Nature, vol. 438, no. 7069, pp. 820–827, 2005.
[80]
S. Hiratsuka, K. Nakamura, S. Iwai et al., “MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis,” Cancer Cell, vol. 2, no. 4, pp. 289–300, 2002.
[81]
S. Hiratsuka, A. Watanabe, H. Aburatani, and Y. Maru, “Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis,” Nature Cell Biology, vol. 8, no. 12, pp. 1369–1375, 2006.
[82]
S. Hiratsuka, A. Watanabe, Y. Sakurai et al., “The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase,” Nature Cell Biology, vol. 10, no. 11, pp. 1349–1355, 2008.
[83]
B. Grum-Schwensen, J. Klingelhofer, C. H. Berg et al., “Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene,” Cancer Research, vol. 65, no. 9, pp. 3772–3780, 2005.
[84]
I. Cornil, D. Theodorescu, S. Man, M. Herlyn, J. Jambrosic, and R. S. Kerbel, “Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 14, pp. 6028–6032, 1991.
[85]
J. T. O'Connell, H. Sugimoto, V. G. Cooke et al., “VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 38, pp. 16002–16007, 2011.
[86]
G. Bergers and L. E. Benjamin, “Tumorigenesis and the angiogenic switch,” Nature Reviews Cancer, vol. 3, no. 6, pp. 401–410, 2003.
[87]
J. Folkman and P. A. D'Amore, “Blood vessel formation: what is its molecular basis?” Cell, vol. 87, no. 7, pp. 1153–1155, 1996.
[88]
D. Lyden, K. Hattori, S. Dias et al., “Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth,” Nature Medicine, vol. 7, no. 11, pp. 1194–1201, 2001.
[89]
N. Takakura, T. Watanabe, S. Suenobu et al., “A role for hematopoietic stem cells in promoting angiogenesis,” Cell, vol. 102, no. 2, pp. 199–209, 2000.
[90]
D. G. DeNardo, M. Johansson, and L. M. Coussens, “Immune cells as mediators of solid tumor metastasis,” Cancer and Metastasis Reviews, vol. 27, no. 1, pp. 11–18, 2008.
[91]
E. Y. Lin and J. W. Pollard, “Tumor-associated macrophages press the angiogenic switch in breast cancer,” Cancer Research, vol. 67, no. 11, pp. 5064–5066, 2007.
[92]
L. A. Liotta and E. C. Kohn, “The microenvironment of the tumour—host interface,” Nature, vol. 411, no. 6835, pp. 375–379, 2001.
[93]
P. D. Brown and R. Giavazzi, “Matrix metalloproteinase inhibition: a review of anti-tumour activity,” Annals of Oncology, vol. 6, no. 10, pp. 967–974, 1995.
[94]
A. Jones and P. Ellis, “Potential withdrawal of bevacizumab for the treatment of breast cancer,” BMJ, vol. 343, no. 7818, article d4946, 2011.
[95]
S. E. Pories and G. M. Wulf, “Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review,” Breast Cancer: Targets and Therapy, vol. 2, pp. 37–44, 2010.
[96]
M.-H. Wu, H.-C. Hong, T.-M. Hong, W.-F. Chiang, Y.-T. Jin, and Y.-L. Chen, “Targeting galectin-1 in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression,” Clinical Cancer Research, vol. 17, no. 6, pp. 1306–1316, 2011.
[97]
B. G. Kim, H. J. An, S. Kang et al., “Laminin-332-rich tumor microenvironment for tumor invasion in the interface zone of breast cancer,” American Journal of Pathology, vol. 178, no. 1, pp. 373–381, 2011.
[98]
K. L. Cook, L. J. Metheny-Barlow, E. A. Tallant, and P. E. Gallagher, “Angiotensin-(1–7) reduces fibrosis in orthotopic breast tumors,” Cancer Research, vol. 70, no. 21, pp. 8319–8328, 2010.
[99]
Y. Liu, P. Jiang, K. Capkova et al., “Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy,” Cancer Research, vol. 71, no. 20, pp. 6492–6502, 2011.
[100]
L. Coenegrachts, C. Maes, S. Torrekens et al., “Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation,” Cancer Research, vol. 70, no. 16, pp. 6537–6547, 2010.
[101]
L. Truitt, T. Freywald, J. DeCoteau, N. Sharfe, and A. Freywald, “The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells,” Cancer Research, vol. 70, no. 3, pp. 1141–1153, 2010.
